| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Delcath Systems Inc. | HEPZATO | Liver-Dominant Metastatic Breast Cancer | Phase 2 | IND Clearance | Intra-arterial | Oncology |
| Delcath Systems Inc. | HEPZATO | Liver-Dominant Metastatic Colorectal Cancer | Phase 2 | Enrollment Initiation | Intra-arterial | Oncology |
| Denali Therapeutics Inc. | BIIB122 - (LUMA) | Parkinson's disease | Phase 2b | Ongoing | Oral | Neurology |
| Denali Therapeutics Inc. | DNL758 (SAR443122) | Cutaneous lupus erythematosus | Phase 2 | Trial Completed | oral | Immunology |
| Denali Therapeutics Inc. | BIIB122 (DNL151) - (LIGHTHOUSE) | Parkinson's Disease Associated with LRRK2 Pathogenic Mutations | Phase 3 | Oral | Neurology | |
| Denali Therapeutics Inc. | DNL788 (SAR443820) - (HIMALAYA) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Oral | Neurology | |
| Denali Therapeutics Inc. | DNL758 (SAR443122) | Cutaneous lupus erythematosus | Phase 2 | Trial Completed | oral | Immunology |
| Denali Therapeutics Inc. | DNL788 (SAR443820) - (HIMALAYA) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Oral | Neurology |